The Myth of the Identical Diagnosis
Why Two Patients Get Different Prescriptions
Imagine two patients, both diagnosed with Major Depressive Disorder. One leaves the doctor’s office with a prescription for sertraline (Zoloft). The other, with the same diagnosis, is given bupropion (Wellbutrin). A third might be given no medication at all, but a referral for cognitive-behavioral therapy. To an observer, this seems inconsistent. But in psychiatry, the diagnosis is just the starting point. The treatment is tailored to the person who has the diagnosis.
The first major variable is symptom profile. Major Depressive Disorder is a heterogeneous condition. Patient A might present with classic melancholic features: early morning awakening, profound weight loss, psychomotor agitation, and crushing guilt. For this patient, an SSRI like escitalopram is often highly effective. Patient B, however, might present with atypical features: hypersomnia (sleeping 12 hours a day), increased appetite, leaden paralysis (a heavy, leaden feeling in the limbs), and extreme rejection sensitivity. For this patient, an SSRI can sometimes be less effective or even exacerbate fatigue. An MAOI or, more commonly, an SNRI or bupropion, might be a better fit. The same diagnosis, but the “subtype” dictates a different pharmacological approach.
The second variable is comorbidity. Few patients have just one diagnosis. Patient A might have depression and an anxiety disorder. An SSRI is a perfect choice, as it is first-line for both. Patient B might have depression and attention-deficit/hyperactivity disorder (ADHD). Bupropion, which has a mild dopaminergic effect, might be chosen because it can address both the depressive symptoms and some of the executive dysfunction of ADHD. Patient C might have depression and chronic pain. For them, duloxetine (Cymbalta), an SNRI approved for both depression and chronic musculoskeletal pain, becomes the logical choice.
The third variable is the patient’s biology and history. A 22-year-old athlete who is concerned about weight gain and sexual function will likely have a different conversation than a 70-year-old man with a history of falls and glaucoma. For the young athlete, a doctor might avoid SSRIs known for sexual side effects and weight gain, possibly opting for bupropion. For the elderly man, the doctor will avoid anticholinergic medications (like TCAs) that cause confusion, constipation, and increase fall risk, instead opting for a low-dose SSRI with a short half-life to minimize drug accumulation.
Finally, genetics and metabolism play a role. Two people taking the same dose of the same medication can have wildly different blood levels due to genetic variations in liver enzymes (CYP450 system). A patient who is a “poor metabolizer” of a drug like fluvoxamine will have dangerously high levels on a standard dose, while an “ultra-rapid metabolizer” will get no benefit. While pharmacogenetic testing is not yet a universal first step, clinicians are increasingly using it to explain past failures and guide future choices.
In essence, psychiatric treatment is not “one size fits all.” It is a bespoke process where the diagnosis provides the framework, but the patient’s unique symptom profile, co-occurring conditions, lifestyle, age, and genetic makeup fill in the details.